MedTrace Logo

Focal Therapy in Localized Prostate Cancer: a Prospective Registry

NCT06772116 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-01-13

No results posted yet for this study

Summary

The principal aim of the registry is to collect data on focal therapy (FT) for the treatment of intermediate-risk prostate cancer across Europe. Data will be gathered on cancer absence following treatment, survival rates, and the absence of disease failure or progression. Information will be collected from as many centers as possible over the next 5 years to enhance understanding of when focal therapy should be used, which energy types are most effective, and how patients respond to treatment, including its side effects and impact on quality of life.

This Europe-wide data collection will contribute to improving care by informing the development of enhanced national and international guidelines for prostate cancer treatment with focal therapy.

Conditions

Interventions

PROCEDURE

Focal Therapy

Primary focal treatment (targeted or partial gland ablation) of PCa lesion(s) detected on mpMRI, where a PCa ISUP 2 or 3 has been identified (PCa ISUP 1 outside the treatment areas is acceptable, regardless of volume). Focal treatment will be performed using one of the following energy-based techniques: high-intensity focused ultrasound (HIFU), cryotherapy (CRYO), brachytherapy (BT), irreversible electroporation (IRE), focal laser ablation (FLA), vascular-targeted photodynamic therapy (VTP), or radiofrequency ablation (RFA). The specific technique will depend on the rules, approvals, and regulations of the country where the treatment is performed.

Sponsors & Collaborators

  • European Association of Urology Research Foundation

    collaborator OTHER

  • Institut Mutualiste Montsouris

    lead OTHER

Principal Investigators

  • Eric Barret, MD, PhD · Institut Mutualiste Montsouris

  • Juan I Martinéz-Salamanca, MD, PhD · Lyx Institute of Urology

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2028-02-29
Completion
2032-02-29

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06772116 on ClinicalTrials.gov